Know When to Refer Patients for New COVID-19 Monoclonal Antibodies
Bamlanivimab and casirivimab/imdevimab will be the first meds authorized to treat OUTPATIENTS with COVID-19.
These new monoclonal antibodies block SARS-CoV-2 from entering cells. Both meds are single-dose IV infusions given over 1 hour.
They're being given at many locations, such as infusion centers...pop-up sites (tents, etc)...long-term care...or even patients' homes.